Aktuelles zur Pflastertechnologie unter spezieller Berücksichtigung des Rotigotinpflasters

Zusammenfassung

Die kutane Applikation von Arzneistoffen hat in den vergangenen Jahren beträchtlich an Bedeutung gewonnen. Es lassen sich über diesen Weg unter Umgehung des First-past-Effektes kontrollierbare, konstante Blutspiegel erzielen, und die geringere Applikationshäufigkeit insbesondere mit transdermalen Pflastern wirkt sich positiv auf die Compliance aus. Der Wirkstoff Rotigotin bietet aufgrund seiner physikalisch-chemischen Eigenschaften wie hohe Lipophilie, niedriger Schmelzpunkt und damit gute Löslichkeit im Stratum corneum und dem niedrigen Molekulargewicht gute Voraussetzungen für die kutane Applikation mit angestrebter systemischer Wirkung.

Abstract

The cutaneous administration of drugs has considerably gained importance over the last years. By this route controlled, constant blood levels can be achieved, the first-pass effect can be avoided, and the lower application frequency, especially of transdermal patches, has a highly positive effect on compliance. On account of its physico-chemical properties such as high lipophilicity, low melting point and thus good solubility in the stratum corneum, as well as its low molecular weight, the drug rotigotine offers excellent prerequisites for cutaneous administration with a desired systemic action.

Matrix - kutane Penetration

matrix - cutaneous penetration

Literatur

• 1 Zaffaroni A. Medical Bandage. US Patent 1976 3, 996, 934
• 2 Cleary G W. The first two decades of transdermal drug delivery and a peak into the 1990's. In: Gurny R, Teubner A (eds) Dermal and Transdermal Drug Delivery. Stuttgart; Wissenschaftliche Verlagsgesellschaft mbH 1993
• 3 Hadgraft J. Pharmaceutical aspects of transdermal nitroglycerin.  Int J Pharm. 1996;  135 1-11
• 4 Wolff M, Cordes G. et al . In vitro and in vivo release of nitroglycerin from a new transdermal therapeutic system.  Pharm Res. 1985;  2 1-54
• 5 Flynn G L. Topical and transdermal delivery - provinces of realism. In: Gurny R, Teubner A (eds) Dermal and Transdermal Drug Delivery. Stuttgart; Wissenschaftliche Verlagsgesellschaft mbH 1993
• 6 Hopp M S. Developing custom adhesive systems for transdermal drug delivery products.  Pharm Technol. 2002;  3 30-36
• 7 Roy S D. Preformulation aspects of transdermal drug delivery systems. In: Ghosh TK, Pfister WR, Yum SI (eds) Transdermal and Topical Drug Delivery Systems. Buffalo Grove; Interpharm Press 1997: 139-166
• 8 Tapash K, Ghosh T K. et al .Transdermal and topical delivery systems: an overview and future trends. In: Ghosh TK, Pfister WR, Yum SI (eds) Transdermal and Topical Drug Delivery Systems. Buffalo Grove; Interpharm Press 1997: 1-32
• 9 Tronnier H. Arzneitherapie an der Haut.  Pharm Ztg. 1977;  122 2021-2027
• 10 Williams A C, Barry B W. Penetration enhancers.  Adv Drug Delivery Rev. 2004;  56 603-618
• 11 Huschka C. Untersuchungen zur Wirkung von Biotin auf humane Keratinozyten und zur Modulation der Biotinpenetration in humane Haut. Halle; Ph. D. Thesis, Martin-Luther-Universität 1998
• 12 Elias P M. Lipids and the epidermal permeability barrier.  Arch Dermatol Res. 1981;  270 95-117
• 13 Menon G K. New insights into skin structure: scratching the surface.  Adv Drug Delivery Rev. 2002;  54, Suppl 1 3-17
• 14 Aungst B J, Rogers N J. et al . Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides.  Int J Pharm. 1986;  33 225-234
• 15 Barry B W. Mode of action of penetration enhancers in human skin.  J Controlled Release. 1987;  6 85-97
• 16 Walker R B, Smith E W. The role of percutaneous penetration enhancers.  Adv Drug Delivery Rev. 1996;  18 295-301
• 17 Friend D, Catz P. et al . Transdermal delivery of levonorgestrel I: Alkanols as permeation enhancers in vitro.  J Controlled Release. 1988;  7 243-250
• 18 Moser K, Kriwet K. et al . Passive skin penetration enhancement and its quantification in vitro.  Eur J Pharm Biopharm. 2001;  52 103-112
• 19 Denet A R, Vanbever R. et al . Skin electroporation for transdermal and topical delivery.  Adv Drug Delivery Rev. 2004;  56 659-674
• 20 Kalia Y N, Naik A. et al . Iontophoretic drug delivery.  Adv Drug Delivery Rev. 2004;  56 619-658
• 21 Mitragotri S, Kost J. Low-frequency sonophoresis: A review.  Adv Drug Delivery Rev. 2004;  56 589-601
• 22 Prausnitz M R. Microneedles for transdermal drug delivery.  Adv Drug Delivery Rev. 2004;  56 581-587
• 23 Tan H S, Pfister W R. Pressure-sensitive adhesives for transdermal drug delivery systems.  Pharm Sci Technol Today. 1999;  2 60-69
• 24 Venkatraman S, Gale R. Skin adhesives and skin adhesion 1 transdermal drug delivery systems.  Biomaterials. 1998;  19 1119-1136
• 25 Musolf M C. Pressure-sensitive adhesives: Science and engineering. In: Chien W (ed) Transdermal controlled systemic medications. New York; Marcel Dekker 1987: 93-112
• 26 Peterson T A, Wick S M. et al .Design, development, manufacturing, and testing of transdermal drug delivery systems. In: Ghosh TK, Pfister WR and Yum Si (eds) Transdermal and Topical Drug Delivery Systems. Buffalo Grove; Interpharm Press 1997: 259-297
• 27 Higuchi W I. Analysis of data on medicament release from ointments.  J Pharm Sci. 1962;  51 802-804
• 28 Crank J. Mathematics of diffusion. Oxford; Clarendon Press 1975
• 29 Schmidt R J. Cutaneous side effects in transdermal drug delivery: Avoidance strategies. In: Hadgraft J, Guy RH (eds) Transdermal Drug Delivery. New York; Marcel Dekker 1989: 98-97